Principal Financial Group Inc. Has $3.92 Million Holdings in Teladoc Health, Inc. $TDOC

Principal Financial Group Inc. grew its stake in Teladoc Health, Inc. (NYSE:TDOC) by 22.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 718,712 shares of the health services provider’s stock after buying an additional 130,637 shares during the quarter. Principal Financial Group Inc.’s holdings in Teladoc Health were worth $3,917,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Monaco Asset Management SAM lifted its position in Teladoc Health by 159.2% in the 4th quarter. Monaco Asset Management SAM now owns 1,956,947 shares of the health services provider’s stock valued at $13,699,000 after acquiring an additional 1,201,947 shares in the last quarter. Jupiter Asset Management Ltd. raised its stake in shares of Teladoc Health by 293.9% in the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after purchasing an additional 2,880,008 shares during the period. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Teladoc Health in the fourth quarter valued at about $1,225,000. Tejara Capital Ltd acquired a new position in shares of Teladoc Health during the fourth quarter worth about $1,114,000. Finally, OP Asset Management Ltd bought a new position in shares of Teladoc Health during the first quarter worth about $3,487,000. Institutional investors own 76.82% of the company’s stock.

Key Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter loss of $0.21 per share, narrower than the $0.24 loss expected by analysts. Operating cash flow was $64.7 million, and cash and equivalents totaled $774.3 million, providing financial flexibility. Teladoc Q2 earnings report
• Neutral Sentiment: The company’s $416.1 million gross profit and $37.1 million operating loss provide additional detail on quarterly performance, although profitability remained negative. Teladoc Q2 financial metrics
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, below the approximately $627.7 million Wall Street estimate. The decline signals continuing challenges in demand and growth for Teladoc’s virtual-care business. Teladoc Health Reports Second Quarter 2026 Results
• Negative Sentiment: Third-quarter revenue guidance of $569 million to $609 million is below the $629.1 million analyst consensus. The projected loss of $0.20 to $0.30 per share also compares unfavorably with expectations for a $0.17 loss, increasing concerns about near-term earnings momentum.
• Negative Sentiment: Full-year 2026 revenue guidance of about $2.4 billion trails the $2.5 billion consensus estimate, while the company continues to forecast a sizable annual loss of $0.75 to $1.00 per share. These outlook reductions appear to be the primary reason TDOC shares decreased following the release. Teladoc key metrics versus estimates

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TDOC shares. Bank of America boosted their target price on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Citigroup raised their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Canaccord Genuity Group boosted their price objective on shares of Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Teladoc Health currently has a consensus rating of “Hold” and an average target price of $7.57.

Insider Transactions at Teladoc Health

In other news, CEO Charles Divita III sold 19,132 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $145,977.16. Following the transaction, the chief executive officer owned 389,894 shares of the company’s stock, valued at approximately $2,974,891.22. This represents a 4.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $47,275.48. Following the transaction, the insider owned 57,671 shares in the company, valued at approximately $440,029.73. This trade represents a 9.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock worth $299,058 over the last three months. Company insiders own 0.70% of the company’s stock.

Teladoc Health Stock Performance

NYSE TDOC opened at $9.21 on Thursday. The firm has a 50-day moving average of $8.21 and a 200-day moving average of $6.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80. The stock has a market cap of $1.66 billion, a PE ratio of -9.50 and a beta of 2.10. Teladoc Health, Inc. has a 52-week low of $4.40 and a 52-week high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. The business had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. Teladoc Health’s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, sell-side analysts anticipate that Teladoc Health, Inc. will post -0.92 EPS for the current year.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.